Fexofenadine as Adjuvant Therapy in Parkinson Disease
Recruiting now · Phase 2/Phase 3
Conditions studied: Parkinson Disease
In brief
Parkinson's disease (PD) is a chronic, progressive neurological disorder characterized by both motor and non-motor symptoms. PD is the second most common neurodegenerative disorder after Alzheimer's disease and the most common movement disorder. PD has age-related pathology; it is present in 1-2% of the population over 60 years of age. The disease is characterized by a triad of disordered voluntary motor activity in the form of bradykinesia (slowness of movement) or even akinesia (absence of movement),rigidity and postural instability, and a resting tremor of the hands and less commonly the feet.
Key facts
- Study ID
- NCT06785298
- Run by
- Tanta University
- People needed
- 46
- Starts
- 2024-12-10
- Expected to finish
- 2026-12-20
- Last updated by the study team
- 2026-01-21
Who can join
Age: 50 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Tanta University — Tanta, Egypt (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.